Lamivudine (3TC, Epivir)

1 Min Read

Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.

First-Line HIV Treatment

Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds

Sony Salzman

The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.

First-Line HIV Treatment

Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds

Sony Salzman

The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy

Satyajit Das; HIV i-Base

A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy

Satyajit Das; HIV i-Base

Paul E. Sax, M.D.; NEJM Journal Watch

A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.

Policy & Advocacy

Mark Wainberg and the Enduring Importance of 3TC

Paul E. Sax, M.D.; NEJM Journal Watch

Paul Sax, M.D., remembers HIV research pioneer Mark Wainberg, Ph.D., as a "thoughtful virologist" who discovered 3TC's efficacy against HIV.

Policy & Advocacy

Mark Wainberg and the Enduring Importance of 3TC

Paul Sax, M.D., remembers HIV research pioneer Mark Wainberg, Ph.D., as a "thoughtful virologist" who discovered 3TC's efficacy against HIV.

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

HIV Drug Development Pipeline Update, Fall 2014 Edition

Lopinavir/Ritonavir (Kaletra)

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy

Warren Tong

Lopinavir/Ritonavir (Kaletra)

A recent study revealed a surprising result: For the first time ever, an HIV treatment regimen consisting of two drugs was found to work just as well as a three-drug regimen.

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy

Warren Tong

CDC National Prevention Information Network

A recent study revealed a surprising result: For the first time ever, an HIV treatment regimen consisting of two drugs was found to work just as well as a three-drug regimen.

Raltegravir (Isentress)

FDA Says Merck's HIV Drug Gets Generic Threat

CDC National Prevention Information Network

1 Min Read

The Food and Drug Administration reports it has received applications from drugmakers who wish to produce generic versions of the HIV drugs Isentress (Merck & Co.) and Epivir (GlaxoSmithKline). Isentress was approved for use in adult patients in 2007...

Raltegravir (Isentress)

FDA Says Merck's HIV Drug Gets Generic Threat

Courtney Fletcher, Pharm.D.; HIV i-Base

1 Min Read

Ritonavir (Norvir)

Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily

5 Min Read

The issue of dose optimisation is important for several reasons, ranging from finding the right dose for an individual patient that achieves the highest probability of therapeutic success with the lowest risk of adverse events, to as a strategy to de...

Ritonavir (Norvir)

Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily

Courtney Fletcher, Pharm.D.; HIV i-Base

5 Min Read

Benjamin Young, M.D., Ph.D.

Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways

Two of the most frequently prescribed components of combination therapy for HIV are the cytidine nucleoside reverse transcriptase inhibitors lamivudine (3TC, Epivir) and emtricitabine (FTC, Emtriva). They are nearly identical in atomic structure, alt...

Benjamin Young, M.D., Ph.D.

Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways

Brian Conway, M.D., F.R.C.P.C.

Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V

Once a patient has gone through a multitude of treatment regimens, finding a fully suppressive salvage regimen can be impossible. It has long been hypothesized that instead of a complete therapeutic interruption, if the M184V mutation is maintained t...

Brian Conway, M.D., F.R.C.P.C.

Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V

Adverse Events & Comorbidities

Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C

Mark Wainberg, Ph.D.

Adverse Events & Comorbidities

How safe are antiretroviral nucleosides in HIV-infected individuals who are coinfected with hepatitis B or hepatitis C? The question is an important one, because of two reasons: Firstly, up to one third of people with HIV are coinfected with hepatiti...

Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C

Mark Wainberg, Ph.D.